Introduction
Addyi (flibanserin) is a prescription medication designed to treat hypoactive sexual desire disorder (HSDD) in women. Unlike over-the-counter libido supplements, Addyi is an FDA-approved drug with randomized clinical trials supporting its use for appropriately diagnosed HSDD.
The medication is particularly different because it is taken every night rather than immediately before sexual activity. Its goal is to address persistent, distressing low sexual desire rather than provide an immediate physical enhancement during sex.
Quick Summary
| Product | Addyi |
|---|---|
| Active Ingredient | Flibanserin |
| Drug Type | Prescription medication |
| Primary Use | Acquired, generalized HSDD |
| Current FDA Indication | Women younger than 65 |
| Dosage | 100 mg once daily at bedtime |
| Hormonal? | No |
| On-Demand Medication? | No |
| Clinical Evidence | Multiple randomized controlled trials |
| Major Safety Issue | Severe hypotension and fainting in certain settings |
| Current Cash Price | $149/month through PHILRx |
The FDA revised Addyi’s indication in December 2025 to include women under 65 with acquired, generalized HSDD, regardless of reproductive status. Addyi is not indicated for men or for enhancing sexual performance.
What Is Addyi?
Addyi is the brand name for flibanserin, a non-hormonal prescription medication. It was initially approved in 2015 for premenopausal women with acquired, generalized HSDD and later received an expanded indication covering women younger than 65.
HSDD is more specific than simply having a low libido. The FDA indication requires low sexual desire that causes significant distress or interpersonal difficulty and is not primarily explained by another medical or psychiatric condition, relationship problems, or a medication or drug.
How Does Addyi Work?
Flibanserin works in the central nervous system rather than acting as a hormone or directly increasing genital blood flow.
It has activity at serotonin receptors and affects neurotransmitter signaling involving serotonin, dopamine, and norepinephrine. The exact mechanism responsible for its clinical effect on sexual desire remains unknown.
This is an important distinction from medications such as sildenafil or tadalafil. Addyi is intended to address sexual desire, whereas PDE5 inhibitors primarily improve the physiological erectile response.
Does Addyi Actually Work?
The evidence for flibanserin comes from multiple randomized, double-blind, placebo-controlled trials.
In a systematic review and meta-analysis of eight randomized trials involving 7,906 women with HSDD, flibanserin 100 mg produced statistically significant improvements in satisfying sexual events, sexual-desire scores, sexual-function measures, and distress compared with placebo in premenopausal women.
An earlier meta-analysis of four randomized trials involving 3,414 women also found improvements in satisfying sexual events, sexual desire, and sexual-function scores compared with placebo.
The magnitude of benefit is important to interpret realistically. Addyi is not designed to produce an immediate or dramatic increase in sexual desire. Clinical trials generally found modest average improvements over placebo, although some women experienced clinically meaningful benefit.
A pooled analysis found that 49.8% of premenopausal women receiving flibanserin reported clinically meaningful overall benefit compared with 33.6% receiving placebo. In the postmenopausal cohort, the corresponding figures were 40.5% and 28.7%.
Evidence in Women After Menopause
The current FDA indication is broader than the original premenopausal indication.
The SNOWDROP randomized trial included naturally postmenopausal women with HSDD. Flibanserin 100 mg at bedtime improved satisfying sexual events, sexual desire, and distress compared with placebo over 24 weeks.
A second trial, PLUMERIA, was stopped early by the sponsor. It still found a statistically significant improvement in the FSFI desire domain, although the difference in satisfying sexual events did not reach statistical significance. The early termination is an important limitation when interpreting this study.
The FDA’s current label now includes women younger than 65 regardless of reproductive status, reflecting the subsequent regulatory evaluation.
Potential Benefits
- Evidence-based treatment: Flibanserin has been evaluated in multiple randomized controlled trials.
- Targets sexual desire: The medication is specifically indicated for HSDD rather than erectile or genital blood-flow problems.
- Non-hormonal: Addyi does not work by replacing estrogen, testosterone, or another sex hormone.
- May reduce distress: Clinical trials measured and reported improvements in distress associated with low desire.
- Expanded eligibility: The current FDA indication covers women younger than 65 regardless of reproductive status.
Pros & Cons
Pros
- FDA-approved prescription treatment for HSDD
- Multiple placebo-controlled clinical trials
- Non-hormonal mechanism
- Evidence includes women after menopause
- Specific indication for persistent, distressing low sexual desire
Cons
- Must be taken every night
- Not an on-demand libido medication
- Benefits are generally modest on average
- Can cause dizziness, sleepiness, nausea, and fatigue
- Alcohol timing restrictions are important
- Significant drug interactions exist
- Not indicated for sexual-performance enhancement
Addyi vs. On-Demand Sexual-Function Medications
| Factor | Addyi | PDE5 Inhibitors |
|---|---|---|
| Active Ingredient | Flibanserin | Examples include sildenafil and tadalafil |
| Primary Target | Sexual desire | Physiological erectile response |
| Approved Use | HSDD in women under 65 | Erectile dysfunction |
| Administration | Daily at bedtime | Usually taken around sexual activity, depending on medication |
| Hormonal | No | No |
| Immediate Effect | No | Intended to facilitate erection when sexually stimulated |
| Alcohol Concern | Yes, particularly close to dosing | Depends on medication and patient factors |
These medications address different aspects of sexual dysfunction. Addyi should not be considered a female equivalent of Viagra because its pharmacology and approved indication are different.
Dosage & How to Take Addyi
The FDA-recommended dosage is 100 mg once daily at bedtime. Taking it at bedtime helps reduce the risk associated with dizziness, low blood pressure, fainting, and central nervous system depression during waking hours.
Addyi is not an as-needed medication. Taking an extra tablet before sexual activity is not the intended use.
If there is no improvement after eight weeks, the current prescribing information recommends discontinuing treatment.
The manufacturer notes that some women may notice changes within four weeks, while others may require longer.
Alcohol & Addyi
Alcohol is one of the most important safety considerations.
Under the current prescribing information, women who consume one or two standard alcoholic drinks should wait at least two hours before taking Addyi at bedtime. If three or more drinks have been consumed that evening, the dose should be skipped. After taking Addyi, alcohol should be avoided until the following day.
This restriction exists because alcohol taken close to Addyi can increase the risk of severe hypotension and fainting.
Side Effects & Safety
The most common adverse reactions reported with Addyi include:
- Dizziness
- Somnolence or sleepiness
- Nausea
- Fatigue
- Insomnia
- Dry mouth
The FDA prescribing information carries a boxed warning concerning hypotension and syncope in certain situations. Addyi can also cause central nervous system depression, particularly when flibanserin exposure increases or when other CNS depressants are involved.
If dizziness or lightheadedness occurs after taking Addyi, the manufacturer advises lying down. Medical attention should be sought if symptoms do not resolve.
Drug Interactions
CYP3A4 inhibitors:
Moderate and strong CYP3A4 inhibitors are contraindicated because they can substantially increase flibanserin exposure and the risk of hypotension and fainting.
Liver disease:
Addyi is contraindicated in women with hepatic impairment because impaired metabolism can increase flibanserin exposure.
CNS depressants:
Other medications or substances that cause sleepiness can increase central nervous system depression.
Herbal supplements:
The manufacturer specifically advises discussing supplements with a healthcare professional and lists St. John’s Wort, ginkgo, and resveratrol among products that should not be taken without medical guidance.
Who May Be a Candidate?
Addyi may be appropriate for women younger than 65 who have acquired, generalized HSDD that causes significant distress or interpersonal difficulty and is not primarily caused by another condition, medication, drug, or relationship problem.
A healthcare professional needs to determine whether the symptoms fit the FDA-approved indication.
Addyi is not indicated for men and is not approved simply to increase sexual performance in women who do not have HSDD.
Who Should Not Take Addyi?
- Women taking moderate or strong CYP3A4 inhibitors
- Women with hepatic impairment
- Anyone with a known allergy to flibanserin or its ingredients
- Women who cannot follow the required alcohol precautions
- People taking medications or supplements that may interact with flibanserin without appropriate medical review
Pregnancy, breastfeeding, low blood pressure, depression or other mental-health conditions, and substance-use history should also be discussed with the prescribing healthcare professional.
Customer Experience
Because Addyi is a prescription medication, patient testimonials should not be treated as evidence of efficacy. The stronger evidence comes from randomized controlled trials and the FDA-reviewed clinical data.
The manufacturer’s website currently features testimonials from women describing changes in sexual desire and satisfaction. These accounts are useful for understanding reported experiences but cannot establish how an individual patient will respond.
Pricing & Access
| Purchase Route | Current Listed Cost |
|---|---|
| Commercial Insurance | As low as $20/month for eligible patients |
| Cash through PHILRx | $149/month |
| Telehealth Visit | Currently advertised at $19 through the manufacturer’s linked service |
| Local Pharmacy | Varies by pharmacy, insurance, and coupon |
The manufacturer currently advertises Addyi at as little as $20 per month for eligible commercially insured patients and $149 per month for cash-paying patients through PHILRx, with free shipping through that service. Pricing and eligibility restrictions apply.
FAQs
What is Addyi?
Addyi is the brand name for flibanserin, a non-hormonal prescription medication used to treat acquired, generalized HSDD in women younger than 65.
What does Addyi treat?
Addyi is specifically indicated for HSDD involving persistently low sexual desire that causes significant distress or interpersonal difficulty and is not explained by another condition, medication, drug, or relationship problem.
Is Addyi FDA approved?
Yes. Addyi received its initial FDA approval in 2015, and the FDA expanded its indication in 2025 to women younger than 65 regardless of reproductive status.
Is Addyi a hormone?
No. Addyi is a non-hormonal medication that acts on neurotransmitter systems in the brain.
How much Addyi should be taken?
The recommended dose is one 100 mg tablet once daily at bedtime.
Can Addyi be taken only before sex?
No. Addyi is not an on-demand medication. It is intended to be taken every night at bedtime.
How long does Addyi take to work?
Some women may notice changes within several weeks. The manufacturer says some patients begin noticing changes around four weeks, while others require more time. Treatment should be discontinued after eight weeks if there is no improvement.
Can Addyi be taken with alcohol?
Alcohol requires specific timing precautions. After one or two standard drinks, the patient should wait at least two hours before taking the bedtime dose; after three or more drinks, the dose should be skipped. Alcohol should be avoided until the following day after taking Addyi.
Does Addyi increase arousal immediately?
No. Addyi is a daily treatment intended to gradually improve HSDD symptoms. It is not designed to produce an immediate, on-demand effect.
Can men take Addyi?
No. Addyi is not indicated for men.
Is Addyi the same as Viagra?
No. Addyi contains flibanserin and targets sexual desire, whereas Viagra contains sildenafil and is approved to treat erectile dysfunction in men.
Final Verdict
Addyi is substantially different from the herbal libido supplements commonly marketed online. It is an FDA-approved prescription medication with multiple randomized controlled trials supporting its use for appropriately diagnosed HSDD. Meta-analyses have found statistically significant improvements in sexual desire, satisfying sexual events, sexual-function measures, and distress compared with placebo.
The evidence should still be interpreted realistically. The average treatment effect is modest, and Addyi does not work as an immediate sexual-performance enhancer. It requires nightly dosing and carries meaningful safety restrictions, particularly concerning alcohol, drug interactions, liver impairment, and hypotension.
The 2025 FDA label expansion is also important. Addyi is now indicated for women younger than 65 regardless of reproductive status, rather than being restricted to premenopausal women as it was under the original indication.
My overall assessment: Addyi is a clinically established prescription option for appropriately diagnosed HSDD, with substantially stronger product-specific evidence than dietary libido supplements. Its main limitations are the modest average benefit, daily dosing, and significant safety and interaction precautions. It should be used under appropriate medical supervision rather than treated as an on-demand sexual-enhancement product.
Our Top Female Libido, Sexual Arousal & Menopause Support Products
We evaluated these products based on key factors relevant to their intended use. Our editorial ratings consider ingredient transparency, available scientific evidence, formulation quality, safety considerations, value, and other product-specific factors.
Provestra
Product Type: Dietary Supplement
Primary Use: Female Libido & Menopause Support
Overall Rating: 4.9/5
Price: $59.00
Key Benefits
- Supports sexual desire and libido
- Supports vaginal lubrication
- Supports sexual sensitivity and satisfaction
- Supports menopause symptom management
Vigorelle
Product Type: Cream/Gel
Primary Use: Sexual Arousal, Lubrication & Sensitivity Support
Overall Rating: 4.8/5
Price: $59.00
Key Benefits
- Supports natural lubrication
- Supports sexual arousal and sensitivity
- Helps enhance sexual sensation
- Supports moisture and comfort
HerSolution
Product Type: Dietary Supplement
Primary Use: Female Libido, Arousal & Sexual Wellness Support
Overall Rating: 4.8/5
Price: $59.95
Key Benefits
- Supports sexual desire and libido
- Supports vaginal lubrication
- Supports sexual arousal and sensitivity
- Supports sexual satisfaction